A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors

Exclusion Criteria

• •Active central nervous system primary or secondary malignancies, active seizure disorder, spinal cord compression, or carcinomatous meningitis.
• •Therapeutic or experimental monoclonal antibodies in last 60 days prior registration.
• •Systemic anticancer therapy or major surgery within 28 days prior to registration. In absence of toxicity from prior systemic anticancer therapy, 5 half-lives since completion of prior systemic anticancer therapy is allowed.
• •Systemic steroids, any other form of immunosuppressive therapy or radiation therapy within 14 days prior to registration.
• •Live vaccine within 30 days prior to registration.
• •Severe hypersensitivity reaction to treatment with another monoclonal antibody, known or suspected hypersensitivity to study drugs or any component of their formulation.
• •History of autoimmune disease or known inflammatory bowel disease.
• •Uncontrolled hypertension (blood pressure \>150/100 mmHg despite optimal medical therapy) or any of the following within 12 months prior to registration: myocardial infarction, congenital long QT syndrome, torsade de points, arrhythmias, right bundle branch block and left anterior hemiblock uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, ongoing NCICTCAE Grade 2 cardiac dysrhythmias, atrial fibrillation or QTcF interval \>470 msec.